I currently lead the US Neurology Business Unit at Alexion, AstraZeneca Rare Disease. The neurology business unit is responsible for assets in gMG (generalized Myasthenia Gravis) and NMOSD (Neuromuscular Optica Spectrum Disorder). As part of my remit, I lead our sales, thought leader liaison and marketing teams across all approved assets in addition to a team that works closely with our global colleagues to ensure launch readiness for late stage neurology pipeline assets. We are a business unit that is four years young and has accomplished much in our short time. Our mission is to deliver life-altering therapies to our patients today and help fund the development of future assets in our rare disease pipeline.

I have a BS in biology from Providence College. Before joining Alexion, I worked for Biogen and have run businesses (and Brands) for them in the US and Europe where I launched four products in neurology, including Multiple Sclerosis. In my last role at Biogen, I was the General Manager of the Canadian Business. In that role, I spun off Bioverativ, launched a new product in MS, and built out their ultra-rare business model for Spinal Muscular Atrophy.

In my career, I have also worked in consumer products for Colgate Palmolive leading their US and North American marketing business. 

I am a big believer in mentoring and continue to mentor (and be mentored by) many of my current and former colleagues.


There is nothing more rewarding than working cross-functionally to help patients gain access to our therapies and then see how that therapy can dramatically change their and their loved ones' quality of life. That is rare disease!

Lisa Hickey Vice President, US Business Unit Lead Neurology

Colgate Palmolive Chairman Award

Colgate Palmolive Chairman’s You Can Make a Difference Reward

Biogen CEO’s

Biogen CEO’s Leading at Biogen Member: Invitational leadership program for top 1% of senior leaders

2021

Alexion Guiding Star Purpose Driven Performance


CURRENT ROLE

Vice President, US Business Unit Lead Neurology

2016

Appointed Vice President and General Manager Biogen Canada where in a one-year period, I spun off a company, launched an new asset into the MS space, and built a new business model for an ultra-rare disease

2013

Headed up Biogen’s EU+ Business Operations team located in Zug, Switzerland during a time of immense change for the organisation


Veeva ID: Z4-42740
Date of preparation: March 2022